Company intelligence / Profile preview

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Nanjing, Jiangsu, Chinadnb.com ↗

Ownership: Private
Employees: ~157
Development stage: Commercial

Overview

The company has several approved drugs including Limertinib (a third-generation EGFR-TKI) for EGFR T790M+ NSCLC approved in January 2025. Other products include Dexlansoprazole, Omeprazole Sodium, and Dexrazoxane Hydrochloride which are already approved. ASKC109 (maltol iron capsules) and ASKB589 (Claudin18.2 monoclonal antibody) are in Phase III clinical trials.

Therapeutic areas: OtherOncologyGastroenterologyInfectious Diseases
Modalities: Small molecule drugsBispecific antibodiesBiosimilarsFusion proteinsColony-stimulating factors
Industry: Biotech

Drug pipeline

12 assets

limertinib

11 more assets in the full pipeline.

Request access →

Partnerships

Innovent (strategic collaboration for Limertinib)

Beyond the preview

Go deeper on Jiangsu Aosaikang Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Aosaikang Pharmaceutical Co., Ltd..

Explore the full profile